Drugs - Xagena.net - Update in Medicine

Search results for "Psoriasis"

Humira, approved in Europe for children and adolescents from four years of age with severe chronic plaque psoriasis

The European Commission ( EC ) has granted marketing authorization for Humira ( Adalimumab ) for the treatment of severe chronic plaque psoriasis in children and adolescents from four years of age who ... read article

Secukinumab, the first interleukin-17A inhibitor, is effective in psoriatic arthritis

Two pivotal phase III studies ( FUTURE 1 and FUTURE 2 ) of Secukinumab ( AIN457 ) in psoriatic arthritis ( PsA ) met primary and key secondary endpoints. Endpoints included improving signs and sympt ... read article

CHMP positive opinion for Cimzia in active psoriatic arthritis

The European Medicines Agencys ( EMAs ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending extending the European Union marketing authorization for t ... read article

Dipeptidyl peptidase-4 inhibitors may also reduce the risk of autoimmune diseases in patients with type 2 diabetes

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients. Dipeptidyl peptidase- ... read article

Inflectra the first biosimilar monoclonal antibody to be approved in Europe

Hospira has announced the European Commission ( EC ) approval of Inflectra ( Infliximab ), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of ... read article

Psoriasis: oral Apremilast achieves statistical significance for the primary endpoint of PASI-75 in the ESTEEM 1

The results from ESTEEM 1 for the treatment of psoriasis were presented at the American Academy of Dermatology annual meeting. ESTEEM 1 evaluated efficacy and safety in a range of patients. Approximat ... read article

Ustekinumab ( Stelara ), an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohns Disease, according to researchers at ... read article

TNF-alpha blockers: warnings about infection with Legionella and Listeria bacteria

The FDA ( Food and Drug Administration ) has informed healthcare professionals that the Boxed Warning for the entire class of Tumor Necrosis Factor-alpha ( TNF-alpha ) blockers has been updated to inc ... read article

Psoriasis drugs: a comparison between Etanercept and Ustekinumab

Researchers at The University of Manchester ( UK ) have compared the drugs Etanercept ( Enbrel ) and Ustekinumab ( Stelara ), relatively new biological therapies that have proved effective in the man ... read article

Risk of tuberculosis with anti-TNF agents

Treatment with anti-tumor necrosis factor ( TNF ) agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing ... read article

Risk of histoplasmosis and other invasive fungal infections associated with Enbrel

Amgen Canada, on behalf of Immunex, in collaboration with Health Canada, has informed HealthCare Professionals of updated safety information regarding Enbrel ( Etanercept ). Enbrel is a soluble for ... read article

Risk of tuberculosis: higher for patients receiving anti-TNF monoclonal antibody therapy than for those receiving soluble TNF receptor therapy

Treatment with anti-TNF ( tumor necrosis factor ) blockers is recognized as a risk factor for tuberculosis ( TB ) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, a ... read article

TNF blockers linked to increased risk of lymphoma, leukaemia and new-onset psoriasis

The FDA ( Food and Drug Administration ) is requiring the manufacturers of TNF blockers to update the Boxed Warning in the prescribing information to alert healthcare professionals of an increased ris ... read article

Genentech: voluntary withdrawal of Raptiva from the U.S. market

Genentech, the manufacturer of the psoriasis drug Raptiva ( Efalizumab ), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. The company is taking this act ... read article

A case of progressive multifocal leukoencephalopathy in a Raptiva patient

Genentech announced that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy ( PML ) in a 70-year old patie ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article